Skip to main content

Legal Update

Listing of Pre-Revenue Biotech Companies soon to happen in Hong Kong

5 March 2018
Mayer Brown Legal Update

With a view to attracting well-established high growth companies from emerging and innovative sectors to list on the Main Board, The Stock Exchange of Hong Kong Limited (HKSE) has released, for consultation purpose, proposed new rules (the "Proposal") to facilitate:

  1. listing of pre-revenue biotech companies;
  2. listing of companies with weighted voting rights; and
  3. secondary listing of issuers primary listed on The New York Stock Exchange, Nasdaq Stock Market or the Main Market of the London Stock Exchange.

We have discussed the proposed new rules on listing of companies with weighted voting rights (see our Legal Update of 1 March 2018). This article will touch on the changes in connection with the listing of pre-revenue biotech companies. The new secondary listing concessionary route will be discussed in our next Legal Update.

Authors

  • Jeckle Chiu
    T +852 2843 2245
  • Billy K. M. Au
    T +852 2843 2254
The Build a Report feature requires the use of cookies to function properly. Cookies are small text files that are placed on your computer by websites that you visit. They are widely used in order to make websites work, or work more efficiently. If you do not accept cookies, this function will not work. For more information please see our Privacy Policy

You have no pages selected. Please select pages to email then resubmit.